Home > News > Webcast of Conference Call to Discuss NUCRYST Pharmaceuticals' results
September 7th, 2004
Webcast of Conference Call to Discuss NUCRYST Pharmaceuticals' results
Abstract:
The Westaim Corporation will hold a webcast at 9:00 a.m. EDT on Wednesday September 8, 2004 regarding
NUCRYST Pharmaceuticals' results of its first Phase 2a human clinical trial. The investigational drug (NPI 32101) is being studied for atopic dermatitis, a form of eczema, and represents a biological application of nanotechnology.
Source:
PRNewswire
| Related News Press |
Nanomedicine
New molecular technology targets tumors and simultaneously silences two ‘undruggable’ cancer genes August 8th, 2025
New imaging approach transforms study of bacterial biofilms August 8th, 2025
Cambridge chemists discover simple way to build bigger molecules – one carbon at a time June 6th, 2025
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
Announcements
Decoding hydrogen‑bond network of electrolyte for cryogenic durable aqueous zinc‑ion batteries January 30th, 2026
COF scaffold membrane with gate‑lane nanostructure for efficient Li+/Mg2+ separation January 30th, 2026
|
|
||
|
|
||
| The latest news from around the world, FREE | ||
|
|
||
|
|
||
| Premium Products | ||
|
|
||
|
Only the news you want to read!
Learn More |
||
|
|
||
|
Full-service, expert consulting
Learn More |
||
|
|
||